Cannabis News

Cannabis Investing

The 2017 TSX Venture Top 50 is out and 4 cannabis companies have made the list.

Cannabis had a breakout year in 2016, and the inclusion of 4 cannabis companies in 2017 TSX Venture Top 50 clearly shows that there is a lot more to look forward to from this sector.
Companies across different sectors were evaluated via a ranking method that looked at 1,643 companies’ share price, trading volume and market capitalization.
Here is a look at the four cannabis companies that made it into the 2017 TSX Venture Top 50:

Aphria (TSXV:APH)

Aphria is a producer and supplier of medical cannabis in Ontario. In February, the company announced approval to graduate from the TSX Venture Exchange to the TSX, and is set to be finalized on or before May 3, 2017. Upon completion of the final listing requirements, Aphria’s shares will be delisted from the TSX Venture Exchange and will commence trading on the TSX.
Over a one-year period, the company’s share price has gained 457.14 percent.

Emerald Health Therapeutics (TSXV:EMH)

Emerald Health Therapeutics is a company focused on cultivating and selling medical cannabis through the Marihuana for Medical Purposes Regulations (MMPR). The company operates a cultivation facility in Victoria, British Columbia, and is planning to construct a 32 acre hybrid greenhouse facility in metro Vancouver. Emerald sells cannabis-based oils and dried cannabis.
Over a one-year period, the Emerald Health Therapeutics share price has gained 645.45 percent.

OrganiGram Holding (TSXV:OGI)

OrganiGram prides itself in growing organic medical marijuana, licensed under MMPR, and with a production facility in New Brunswick. The company recently found itself facing a proposed class-action lawsuit filed by a Halifax-based firm representing Organigram clients who claim they purchased and consumed their product and found it to contain trace elements of pesticides. In response, the company said it plans to “vigorously defend our company and its actions related to the product recall.” The class-action lawsuit only contains allegations that are not yet tested in court as of March 8, 2017.
Over a one-year period, the company’s share price has gone up by 174.36 percent.

Mettrum Health

Mettrum was acquired by Canopy Growth (TSX:CGC) in December 2016. Canopy Growth operates various brands in marijuana-related companies. The arrangement is anticipated to be completed soon.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Pia Rivera, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Mettrum is a client of the Investing News Network. This article is not paid-for content.


S&P 5003807.20-11.63


Heating Oil3.83-0.12
Natural Gas5.66-0.84